1068 is still up in the air / maybe floating around at sea?? But we need to use the cash / $65M at year end to get us to the magic $100M revenue plateau so we are an M& A candidate / way to small currently. Believe the market / PPS is stalled due to Orencia falling off at year end and nothing to make up for it! I KNWO I KNOW patience so we can get ANOTHER NOVAZYME DEAL! That would be great.
This just in from 10k which states..Our third clinical development program was targeted at Friedrich's Ataxia and led by RG2833, a class I histone deacetylase ("HDAC") inhibitor. RG2833 has received Orphan Drug designation from the FDA and European Commission. We initiated a single, ascending dose Phase 1 study of RG2833 in Friedreich's Ataxia patients in Italy in the fourth quarter of 2012 and expect to complete this trial in the first half of 2013. We believe the results of this trial may be an important consideration for any third-party that may wish to pursue a development or commercialization agreement with us for RG2833. We expect that any additional development activities that we may pursue in the future will be largely supported by sponsors or collaborators.
They must have interest which will leave just RG1068. Secretin which works with water enhancement within pancreas. Well there nothing like it. Optics in ASML machines in lithography water with water submersion .
What I was trying to say is they have to see these to the end. The MRI is magnetic and ASML machines work light using photostatic resist. Just think of taking a camera apart. Repligen needs to take their time on a acquisition. There business is growing that will be enough until something shows up.They used money from Orencia deal. They are ready for transition.( Renewable's are tricky )